pharmaphorum February 23, 2024
An artificial intelligence-powered computer-aided detection (CAD) system developed by Israeli medtech company Magentiq-Eye has been shown to improve detection rates for adenoma – premalignant lesions that can develop into cancer – in a colonoscopy clinical trial.
The study of the Magentiq-Colo software, which was approved by the FDA last year, showed that AI-aided colonoscopy improved adenoma detection rates (ADR) by 7% and reduced the adenoma miss rate (AMR) by 17% compared to conventional colonoscopy.
It was carried out over a period of 14 months across 10 medical centres in Europe, the US, and Israel, and involved 31 endoscopists and 952 screened and enrolled patients
According to the authors of the study, which is published in The Lancet Digital Health journal,...
Today's Sponsors
Today's Sponsor